StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research note issued to investors on Wednesday. The brokerage issued a hold rating on the biotechnology company’s stock.
Pulmatrix Stock Performance
Shares of Pulmatrix stock opened at $1.92 on Wednesday. The company has a market capitalization of $7.01 million, a P/E ratio of -0.80 and a beta of 0.94. The company has a fifty day moving average of $1.94 and a 200 day moving average of $1.89. Pulmatrix has a fifty-two week low of $1.55 and a fifty-two week high of $2.88.
Pulmatrix (NASDAQ:PULM – Get Free Report) last released its quarterly earnings data on Friday, May 10th. The biotechnology company reported $0.23 EPS for the quarter. The business had revenue of $5.89 million during the quarter. Pulmatrix had a negative net margin of 75.73% and a negative return on equity of 44.05%.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Read More
- Five stocks we like better than Pulmatrix
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Campbell Soup Co. Targets Fiscal Q4 Stock Recovery
- Options Trading – Understanding Strike Price
- Zebra Analysts Upgrade Stock, Forecasting Major Reversal
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
